Oncaspar Articles

Italy’s Sigma-Tau to takeover Enzon business for some $327 million in cash plus royalties

10 November 2009

Enzon gets Orphan Drug status for new version of Oncaspar

6 October 2008

Enzon Pharma explores options, including the sale of its specialty drugs unit

18 August 2008

Enzon swings to $286M loss in 4th-qtr 2005

13 March 2006

JPMA issues guidelines for research tool patent

30 January 2006

NPS Pharma and Enzon to merge in $1.6B deal; aim to be "a new biotech leader"

3 March 2003

Enzon regains rights to cancer drug OncaSpar

15 July 2002

Enzon - improving the delivery and side effect profile of proven

20 January 1999

Progress Revealed At Enzon

9 December 1996

Medac To Market Enzon's Oncaspar In Europe And Russia

21 October 1996

2nd Generation EPO Available For License

27 February 1995

New Chemical Entities Round-Up For 1994

6 February 1995

Rhone-Poulenc Rorer Gains Exclusive Oncaspar Rights

16 January 1995

R-PR Receives Approval In Canada

26 September 1994

ENZON'S ONCASPAR APPROVED IN USA

14 February 1994

ENZON GETS APPROVABLE RECOMENDATION

13 December 1993

BIOTECH PRODUCTS INUS DEVELOPMENT

26 July 1993

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end